Abstract
BackgroundThe uptake of biosimilars has been suboptimal in North America. In response, in 2019, British Columbia (BC) became the first jurisdiction in North America to require patients with inflammatory arthritis...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
